Cd40 ligand adjuvant for respiratory syncytial virus

US7371392B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Ralph A. Tripp · Watkinsville, US
• Larry J. Anderson · Blue Springs, US
• Michael Brown · Adelaide, AU

Key dates

• Filing date: Feb 2, 2001
• Grant date: May 13, 2008
• Expiry date: Feb 7, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18634
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.